Repare Therapeutics
RPTX
RPTX was delisted on the 27th of January, 2026.
61 hedge funds and large institutions have $112M invested in Repare Therapeutics in 2024 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 21 increasing their positions, 17 reducing their positions, and 15 closing their positions.
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
24% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 17
4.59% less ownership
Funds ownership: 84.19% → 79.59% (-4.6%)
14% less funds holding
Funds holding: 71 → 61 (-10)
33% less capital invested
Capital invested by funds: $167M → $112M (-$55.7M)
60% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 15
73% less call options, than puts
Call options by funds: $19K | Put options by funds: $70K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Aquilo Capital Management
San Francisco,
California
|
+$1.15M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.01M |
| 3 |
BOCH
Blue Owl Capital Holdings
New York
|
+$892K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$619K |
| 5 |
Squarepoint
New York
|
+$413K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$6.35M |
| 2 |
AG
Artal Group
Luxembourg
|
-$3.3M |
| 3 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
-$1.62M |
| 4 |
HS
HighVista Strategies
Boston,
Massachusetts
|
-$778K |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$318K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Citigroup
New York
| – | -$160 | -34 | Closed |
|
RPTX Hedge Fund Activity: Q2 2024 in Review
61 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Repare Therapeutics (RPTX) for Q2 2024, worth a combined $112M — down 33% from $167M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of RPTX and 6 opened new positions — a net loss of 9 holders — while 17 trimmed existing stakes and 21 added.
The largest buyer was Aquilo Capital Management, adding an estimated $1.15M. The largest seller was Deep Track Capital, cutting an estimated $6.35M.
- 61 institutional investors held Repare Therapeutics (RPTX) as of Q2 2024, down from 71 in Q1 2024.
- Funds reported $112M of Repare Therapeutics stock for Q2 2024, down 33% quarter-over-quarter.
- 6 funds opened new Repare Therapeutics positions in Q2 2024 and 15 closed out, a net change of -9 holders.
- The largest Repare Therapeutics buyer in Q2 2024 was Aquilo Capital Management, an estimated $1.15M added.
- The largest Repare Therapeutics seller in Q2 2024 was Deep Track Capital, an estimated $6.35M sold.
Based on aggregated 13F filings for Q2 2024.